Nearly 38 million people are living with HIV worldwide, yet 16% are unaware of their status and 27% are not accessing treatment.

Unitaid’s work has brought groundbreaking advances to improve the lives of people living with HIV worldwide. With US$1.5 billion invested in testing, treatment, and prevention for adults and children over the past 15 years, Unitaid’s work is enabling more people to access the best quality care, avert illness and death, and helping to drive down HIV transmission globally.

**MAJOR ADVANCES**

**AFFORDABLE PRICES FOR THE BEST TREATMENTS:**

Unitaid and its partners secured a breakthrough pricing agreement that enabled people in resource-limited settings across the world to access the highest quality, single pill HIV treatment regimen containing the drug dolutegravir (DTG) at US$75 per person per year, compared to US$12,000.

**MEDICINES AND DIAGNOSTICS TO FIND AND TREAT CHILDREN:**

By improving access to tools that allowed babies and young children to receive an HIV diagnosis more quickly and easily, and creating child formulations of the best HIV medicines at a 75% cost reduction, Unitaid has driven forward lifesaving advances for children living with HIV.

**WIDE REACHING ACCESS TO HIV SELF-TESTS:**

Unitaid pioneered the introduction of HIV self-tests, which have created a crucial pathway to treatment or prevention services for millions of people. Unitaid’s work has slashed the cost of self-tests, generated demand and led to a 15-fold increase in the number of countries with self-testing policies in place globally, contributing to a nearly 40% increase in the number of people who know their status since 2015.
Major breakthroughs in testing, treatment and prevention in the past 15 years have transformed the lives of people with HIV. But ensuring access to high-quality care for people in resource-limited settings is critical to turning the tide against HIV/AIDS globally.

Unitaid’s investments are currently supporting work that aims to:

• Prevent HIV among populations at highest risk by accelerating uptake of effective pre-exposure prophylaxis (PrEP) options, including the latest, long-acting innovations
• Enable more people to access HIV treatment or prevention services by making self-testing affordable, widely available, acceptable, and integrated into national policies
• Reduce the HIV burden on the youngest and most vulnerable by developing affordable child formulations of the most effective HIV treatments and making them available at record speed
• Ensure infants can be initiated on treatment quickly with access to point-of-care diagnostics and viral load testing
• Reach broader populations through creative multimedia campaigns to raise awareness among young people at risk of HIV infection
• Avert hundreds of thousands of preventable deaths among people with advanced HIV disease by improving access to a package of critical medicines and diagnostics for opportunistic diseases that affect people with compromised immune systems
• Tackle preventable HIV co-infections by advancing critical tools for screening and treatment of cervical cancer and improving access to testing, treatment, and prevention for hepatitis C
• Develop long-lasting HIV medicines that would expand options for treatment and free patients from daily medicines
• Contribute valuable evidence collected through Unitaid projects to shape WHO guidance and advance care for people worldwide

The innovative products and strategies demonstrated through Unitaid’s work enable partners like the Global Fund and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) to scale up these tools and approaches globally.

This work is delivered in close collaboration with our partners and grantees, who include: Clinton Health Access Initiative (CHAI), Elton John AIDS Foundation, Expertise France, Fiocruz, Institute Buisson Bertrand (IBB), Medicines Patent Pool (MPP), MTV Staying Alive Foundation, Population Services International (PSI), Solthis, University of Liverpool, University of New South Wales, University of Washington, Wits RHI, World Health Organization (WHO), and many additional partners supporting implementation.

Unitaid’s donors are: Brazil, Chile, France, Japan, Norway, the Republic of Korea, Spain, the United Kingdom and the Bill & Melinda Gates Foundation. As part of Unitaid’s response to the COVID-19 pandemic and leadership of the ACT-Accelerator, the organization received additional resources from Canada, Germany, Italy, Portugal, and Wellcome.

Unitaid is a hosted partnership of the World Health Organization.